Literature DB >> 17497284

Serum level of vascular endothelial growth factor in patients with obstructive sleep apnea hypopnea syndrome.

Jing Ma1, Yongjian Xu, Zhenxiang Zhang, Huiguo Liu, Weining Xiong, Shuyun Xu.   

Abstract

To explore the relationship between the serum vascular endothelial growth factor (VEGF) level and the severity of obstructive sleep apnea hypopnea syndrome (OSAHS), the concentrations of serum VEGF in 40 OSAHS patients and 9 healthy controls were measured by using ELISA method. Meanwhile the correlation between the concentration of VEGF and parameters of polysomnography (PSG) was examined. Our results showed that the concentrations of VEGF were significantly higher in OSAHS patients with severe hypoxia (536.8+/-334.7 pg/mL) than in those with mild hypoxia (329.2+/-174.7 pg/mL) and healthy controls (272. 8+/-211.0 pg/mL) (P<0.05 for both). The concentrations of VEGF were also significantly higher in OSAHS patients with hypertension (484.5+/-261.4 pg/mL) than in those without hypertension (311.0+/-158.4 pg/mL) and healthy controls (272. 8+/-211.0 pg/mL) (P<0.05 for both). There was a positive correlation between the concentration of VEGF and the apnea hypopnea index (AHI) (r=0.34, P<0.05). It is concluded that the concentration of the serum VEGF is positively related to the severity of OSAHS. The elevated serum VEGF level may be involved in the pathogenesis of the complications of obstructive sleep apnea hypopnea syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497284     DOI: 10.1007/s11596-007-0212-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  15 in total

Review 1.  Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions.

Authors:  C Michiels; T Arnould; J Remacle
Journal:  Biochim Biophys Acta       Date:  2000-06-02

2.  Sympathetic muscle nerve activity during sleep in man.

Authors:  M Hornyak; M Cejnar; M Elam; M Matousek; B G Wallin
Journal:  Brain       Date:  1991-06       Impact factor: 13.501

3.  Arterial blood pressure responses to graded transient arousal from sleep in normal humans.

Authors:  R J Davies; P J Belt; S J Roberts; N J Ali; J R Stradling
Journal:  J Appl Physiol (1985)       Date:  1993-03

Review 4.  Cardiovascular morbidity in obstructive sleep apnea.

Authors:  J W Weiss; S H Launois; A Anand; E Garpestad
Journal:  Prog Cardiovasc Dis       Date:  1999 Mar-Apr       Impact factor: 8.194

5.  Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure.

Authors:  M S Ip; B Lam; L Y Chan; L Zheng; K W Tsang; P C Fung; W K Lam
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

6.  Hypoxia and VEGF mRNA expression in human tumors.

Authors:  L S Ziemer; C J Koch; A Maity; D P Magarelli; A M Horan; S M Evans
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

7.  Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea.

Authors:  David Gozal; Andrew J Lipton; Kimberly L Jones
Journal:  Sleep       Date:  2002-02-01       Impact factor: 5.849

8.  Oxygen administration improves the serum level of nitric oxide metabolites in patients with obstructive sleep apnea syndrome.

Authors:  Shinji Teramoto; Haruki Kume; Takeshi Matsuse; Takeo Ishii; Akira Miyashita; Masahiro Akishita; Kenji Toba; Yasuyoshi Ouchi
Journal:  Sleep Med       Date:  2003-09       Impact factor: 3.492

9.  Plasma vascular endothelial growth factor in sleep apnea syndrome: effects of nasal continuous positive air pressure treatment.

Authors:  Lena Lavie; Holger Kraiczi; Aya Hefetz; Haifa Ghandour; Ana Perelman; Jan Hedner; Peretz Lavie
Journal:  Am J Respir Crit Care Med       Date:  2002-06-15       Impact factor: 21.405

Review 10.  [Effect of sleep apnea syndrome on the vascular endothelium].

Authors:  P-L Tharaux
Journal:  Rev Neurol (Paris)       Date:  2003-11       Impact factor: 2.607

View more
  6 in total

1.  Vascular endothelial growth factor levels in patients with obstructive sleep apnea: a meta-analysis.

Authors:  Xiao-Bin Zhang; Xing-Tang Jiang; Fang-Rong Cai; Hui-Qing Zeng; Yan-Ping Du
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-28       Impact factor: 2.503

2.  Obstructive sleep apnea and acute myocardial infarction severity: ischemic preconditioning?

Authors:  Neomi Shah; Susan Redline; H Klar Yaggi; Richard Wu; C George Zhao; Robert Ostfeld; Mark Menegus; Daniel Tracy; Elizabeth Brush; W David Appel; Robert C Kaplan
Journal:  Sleep Breath       Date:  2012-10-23       Impact factor: 2.816

3.  Serum sex hormone levels in different severity of male adult obstructive sleep apnea-hypopnea syndrome in East Asians.

Authors:  Jia-Qi Dong; Xiong Chen; Ying Xiao; Rui Zhang; Xun Niu; Wei-Jia Kong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

4.  Vascular endothelial growth factor genotypes and haplotypes contribute to the susceptibility of obstructive sleep apnea syndrome.

Authors:  Chao Cao; Qunli Ding; Dan Lv; Zhe Dong; Shifang Sun; Zhongbo Chen; Huahao Shen; Zaichun Deng
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

5.  Serum Levels of Vascular Endothelial Growth Factor and Insulin-like Growth Factor Binding Protein-3 in Obstructive Sleep Apnea Patients: Effect of Continuous Positive Airway Pressure Treatment.

Authors:  Kostas Archontogeorgis; Evangelia Nena; Nikolaos Papanas; Maria Xanthoudaki; Olga Hatzizisi; Georgios Kyriazis; Venetia Tsara; Efstratios Maltezos; Marios Froudarakis; Paschalis Steiropoulos
Journal:  Open Cardiovasc Med J       Date:  2015-12-29

6.  Obstructive Sleep Apnea Monocytes Exhibit High Levels of Vascular Endothelial Growth Factor Secretion, Augmenting Tumor Progression.

Authors:  Carolina Cubillos-Zapata; Enrique Hernández-Jiménez; José Avendaño-Ortiz; Victor Toledano; Anibal Varela-Serrano; Isabel Fernández-Navarro; Raquel Casitas; Carlos Carpio; Luis A Aguirre; Francisco García-Río; Eduardo López-Collazo
Journal:  Mediators Inflamm       Date:  2018-05-28       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.